Abstract
The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% Cl = 65-92%] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.
| Original language | English |
|---|---|
| Pages (from-to) | 1166-1171 |
| Number of pages | 6 |
| Journal | British Journal of Cancer |
| Volume | 84 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - May 4 2001 |
Fingerprint
Keywords
- Paclitaxel
- Small cell lung cancer
- Topotecan
- Weekly chemotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer : A phase II study. / Frasci, G.; Nicolella, G.; Comella, P.; Carreca, I.; DeCataldis, G.; Muci, D.; Brunetti, C.; Natale, M.; Piantedosi, F.; Russo, A.; Palmeri, S.; Comella, G.; Panza, N.
In: British Journal of Cancer, Vol. 84, No. 9, 04.05.2001, p. 1166-1171.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer
T2 - A phase II study
AU - Frasci, G.
AU - Nicolella, G.
AU - Comella, P.
AU - Carreca, I.
AU - DeCataldis, G.
AU - Muci, D.
AU - Brunetti, C.
AU - Natale, M.
AU - Piantedosi, F.
AU - Russo, A.
AU - Palmeri, S.
AU - Comella, G.
AU - Panza, N.
PY - 2001/5/4
Y1 - 2001/5/4
N2 - The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% Cl = 65-92%] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.
AB - The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 μg/kg days 3-5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% Cl = 65-92%] ORR. At a 13-month (range, 4-26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches.
KW - Paclitaxel
KW - Small cell lung cancer
KW - Topotecan
KW - Weekly chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=17844406865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844406865&partnerID=8YFLogxK
U2 - 10.1054/bjoc.2001.1741
DO - 10.1054/bjoc.2001.1741
M3 - Article
C2 - 11336465
AN - SCOPUS:17844406865
VL - 84
SP - 1166
EP - 1171
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 9
ER -